Bionic nanoparticles are expected to be a mucous membrane adjunct to the universal flu vaccine

。 Adjunct activity mediated by PS-GAMP.
Fudan University School of Basic Medicine and Jiang Shibo team, in collaboration with Associate Professor Mei X Wu of The Massachusetts General Hospital of Harvard Medical School, have revealed the role and mechanism of bionic nanoparticles as mucous membrane admissors for the universal influenza vaccine. The study was published in Science on February 21st in the form of Research Article. The paper is entitled "Bionic nanoparticles (PS-GAMP), an active substance in the vesicles, enhances resistance to influenza virus infection."
influenza virus can cause 3 million to 5 million serious infections and 25-69 million deaths each year, which poses a great threat to people's lives and health. Because the hematinin (HA) and neural anase (NA) genes of influenza viruses often mutate, the mismatch between the newer strains and the epidemic strains is predicted each year, greatly limiting the effectiveness and application of vaccines. Compared with the natural infection of the virus and the replication vaccine such as the detoxifying live vaccine, the mucous membrane T-cell immune response caused by the non-replica replicated vaccine is poor and cannot induce a strong protective immune response. Therefore, there is an urgent need for safe and efficient mucous membrane adjuncts to promote protective immunity to the body in response to the threat of different influenza virus infections.
's research team developed a lung bionic nanoparticle (PS-GAMP) based on cGAMP design to simulate lung infections of influenza viruses and found that it was able to activate AMs and AECs without damaging the pulmonary surfactant (PS) and the altrual superstorm barrier (AEC) to promote an efficient body fluid and CD8-T cell-protected immune response to protect against multiple iso-type influenza viruses. The results suggest that AECs play an important role in producing broad cross-protection against various influenza viruses, suggesting that PS-GAMP may be a potential mucous membrane adjunct to a "universal" influenza vaccine.
Land Researcher and Professor Jiang Shibo team has long been committed to China's new re-communicable disease drugs, vaccine research, MeiX Wu Associate Professor team focused on bionic delivery systems, ad adhesives and other research, the results of the two teams work together, carried out nearly 5 years of research work. Currently, the team is focusing on research into new coronavirus drugs and vaccines, and the results provide an important technical basis for vaccine research to effectively prevent new coronavirus infections.
that Fudan University Biosecurity Level III Laboratory and the Public Instrument Platform of the Basic Medical College have given important support to the research. (Source: Huang Xin, China Science Journal)
relevant paper information: